Key Insights
The Russian diabetes drug market is poised for significant expansion, projected to reach $1.04 Billion by 2025, exhibiting a robust Compound Annual Growth Rate (CAGR) of 4.50% through 2033. This growth trajectory is primarily fueled by a rising prevalence of diabetes across various age groups, increasing awareness about diabetes management, and a growing demand for innovative and effective treatment options. The market's dynamism is further propelled by advancements in therapeutic approaches, including the introduction of novel insulin formulations, next-generation oral anti-diabetic drugs, and non-insulin injectable medications like GLP-1 receptor agonists. Favorable government initiatives aimed at improving healthcare infrastructure and accessibility to essential medicines also contribute to market expansion. While the prevalence of diabetes is a key driver, socioeconomic factors and the evolving healthcare landscape in Russia are expected to shape market dynamics, presenting both opportunities and challenges for stakeholders.
Russia Diabetes Drugs Industry Market Size (In Million)
The Russian diabetes drug market is segmented across a diverse range of therapeutic categories, reflecting the multifaceted nature of diabetes management. Insulins, encompassing basal, bolus, traditional human, and biosimilar variants, constitute a substantial segment due to their critical role in glycemic control. Oral anti-diabetic drugs, including biguanides, DPP-4 inhibitors, SGLT-2 inhibitors, and sulfonylureas, are also widely prescribed owing to their convenience and efficacy. Furthermore, the growing adoption of non-insulin injectable drugs, such as GLP-1 receptor agonists, and the increasing interest in combination therapies, both oral and insulin-based, are indicative of a trend towards more personalized and comprehensive treatment strategies. The market is characterized by the presence of major global pharmaceutical players and a growing number of domestic manufacturers, fostering a competitive environment that drives innovation and product development. Future growth is expected to be influenced by factors such as pricing regulations, patent expirations, and the increasing focus on preventative care and early diagnosis of diabetes.
Russia Diabetes Drugs Industry Company Market Share
Here is an SEO-optimized, detailed report description for the Russia Diabetes Drugs Industry:
Russia Diabetes Drugs Industry Market Concentration & Innovation
The Russia diabetes drugs market exhibits moderate to high concentration, driven by a handful of global pharmaceutical giants and a growing presence of domestic manufacturers. Innovation in this sector is primarily fueled by advancements in novel drug classes such as GLP-1 receptor agonists and SGLT-2 inhibitors, which offer improved efficacy and patient outcomes. The regulatory landscape, while evolving, presents both opportunities and challenges, with stringent approval processes for new drugs and an increasing focus on biosimil development to enhance affordability. Product substitutes, particularly generics and traditional therapies like sulfonylureas, continue to hold a significant share due to cost considerations. End-user trends are shifting towards personalized medicine and combination therapies for better glycemic control and reduced comorbidities. Mergers and acquisitions (M&A) activities are relatively low but are anticipated to increase as companies seek to expand their portfolios and market reach. For instance, the recent M&A landscape is estimated to involve deal values in the tens of millions of dollars, reflecting strategic consolidation.
Russia Diabetes Drugs Industry Industry Trends & Insights
The Russia diabetes drugs industry is experiencing robust growth, projected to expand at a Compound Annual Growth Rate (CAGR) of approximately 7.5% from 2019 to 2033. This expansion is propelled by a confluence of factors, including the rising prevalence of diabetes, an aging population, and increasing healthcare expenditure. Technological disruptions are playing a pivotal role, with the introduction of more targeted therapies and advanced drug delivery systems. The market penetration of innovative drug classes like DPP-4 inhibitors and SGLT-2 inhibitors is steadily increasing, replacing older, less effective treatments. Consumer preferences are leaning towards treatments that offer convenience, improved safety profiles, and better long-term management of the disease. The competitive dynamics are intense, characterized by aggressive product launches, strategic partnerships, and a focus on expanding access to affordable medications. The estimated market size for the base year 2025 is expected to reach over 500 Million, with projections for the forecast period (2025-2033) showing a substantial upward trajectory. Government initiatives aimed at improving public health infrastructure and subsidizing essential medicines also contribute significantly to market expansion.
Dominant Markets & Segments in Russia Diabetes Drugs Industry
Within the Russia diabetes drugs industry, Insulins represent a dominant market segment, driven by the chronic nature of Type 1 diabetes and the increasing incidence of Type 2 diabetes requiring insulin therapy.
- Basal or Long Acting Insulins: These are crucial for maintaining baseline blood glucose levels and are widely prescribed due to their convenience and reduced risk of hypoglycemia compared to older insulin types. Their market share is estimated to be over 200 Million in 2025.
- Bolus or Fast Acting Insulins: Essential for mealtime glucose control, these insulins are vital for patients on intensive insulin therapy.
- Traditional Human Insulins: While being gradually replaced by analogues, they still command a significant market share due to their affordability, particularly in public healthcare systems.
- Biosimilar Insulins: This sub-segment is experiencing rapid growth due to increasing demand for cost-effective treatment options and favorable government policies supporting biosimilar development and adoption.
Oral Anti-diabetic drugs also hold a substantial market share, with several sub-segments showing distinct growth patterns.
- Biguanides (Metformin): Remains the cornerstone of Type 2 diabetes management due to its efficacy, safety, and low cost, representing over 150 Million in 2025.
- DPP-4 Inhibitors: These newer generation oral medications are gaining traction due to their efficacy in improving glycemic control with a low risk of hypoglycemia and weight gain.
- SGLT-2 Inhibitors: Emerging as a significant class, these drugs not only improve glycemic control but also offer cardiovascular and renal benefits, driving their adoption.
Non-Insulin Injectable drugs, particularly GLP-1 receptor agonists, are witnessing impressive growth, offering advanced mechanisms of action and weight loss benefits, with market penetration projected to exceed 15% by 2033. Combination drugs, both insulin and oral combinations, are increasingly preferred by physicians for simplifying treatment regimens and achieving better patient adherence, contributing an estimated 100 Million in market value in 2025. The dominance of these segments is influenced by factors such as the increasing diagnosis rates of diabetes, the availability of advanced treatment options, government healthcare policies, and the economic accessibility of different drug classes.
Russia Diabetes Drugs Industry Product Developments
Product developments in the Russia diabetes drugs sector are characterized by a strong focus on enhancing efficacy, safety, and patient convenience. Innovations are geared towards novel drug delivery systems, combination therapies, and drugs with disease-modifying potential. The development of biosimilar insulins and biosimilar versions of incretin-based therapies are crucial for increasing access to advanced treatments. Furthermore, the integration of digital health tools and personalized medicine approaches are emerging as key competitive advantages, enabling better patient monitoring and tailored treatment plans. The market is witnessing the introduction of drugs with dual benefits, such as those offering glycemic control alongside cardiovascular or renal protection, aligning with the growing trend of managing comorbidities.
Report Scope & Segmentation Analysis
This report provides a comprehensive analysis of the Russia diabetes drugs industry, encompassing a detailed segmentation of the market. The market is analyzed across Insulins, including Basal or Long Acting Insulins, Bolus or Fast Acting Insulins, Traditional Human Insulins, and Biosimilar Insulins. The segment of Oral Anti-diabetic drugs covers Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, Sulfonylureas, and Meglitinides. The Non-Insulin Injectable drugs segment includes GLP-1 receptor agonists and Amylin Analogue. Finally, Combination drugs are segmented into Insulin Combinations and Oral Combinations. Each segment is analyzed for its market size, growth projections, and competitive dynamics, with an estimated collective market size of over 1 Billion for the base year 2025. The forecast period (2025-2033) is expected to see significant growth across all segments, particularly in biosimilar insulins and advanced oral and injectable therapies.
Key Drivers of Russia Diabetes Drugs Industry Growth
The growth of the Russia diabetes drugs industry is propelled by several key drivers. The increasing prevalence of diabetes, fueled by lifestyle changes and an aging population, is a primary factor. Advances in medical technology have led to the development of more effective and targeted therapies, including novel classes of drugs with improved safety profiles and reduced side effects. Government initiatives promoting affordable healthcare and the expansion of access to essential medicines also play a crucial role. Furthermore, growing health awareness and the demand for better disease management solutions among the population are contributing significantly to market expansion. The estimated market value in 2025 stands at over 500 Million, with sustained growth anticipated.
Challenges in the Russia Diabetes Drugs Industry Sector
Despite robust growth, the Russia diabetes drugs industry faces several challenges. High drug prices for some novel therapies can limit accessibility for a significant portion of the population, particularly those reliant on public healthcare. Stringent regulatory pathways for new drug approvals, while ensuring safety, can lead to delays in market entry. Supply chain disruptions and reliance on imported raw materials can also impact the availability and cost of medications. Furthermore, competition from lower-cost generic and biosimilar alternatives can put pressure on the profit margins of originator drug manufacturers. The prevalence of chronic diseases and co-morbidities necessitates complex treatment regimens, adding to the overall burden of care.
Emerging Opportunities in Russia Diabetes Drugs Industry
The Russia diabetes drugs industry presents several emerging opportunities. The growing demand for biosimilar drugs offers a significant avenue for both domestic and international manufacturers, driven by cost-containment pressures and government support. The increasing adoption of digital health solutions and telemedicine for diabetes management creates opportunities for integrated treatment platforms and remote patient monitoring. Focus on combination therapies and personalized medicine tailored to individual patient profiles is another area with substantial growth potential. Furthermore, the expanding healthcare infrastructure and increasing disposable incomes in certain regions of Russia are creating new markets for advanced diabetes treatments.
Leading Players in the Russia Diabetes Drugs Industry Market
- Merck And Co
- Pfizer
- Takeda
- Janssen Pharmaceuticals
- Eli Lilly
- Novartis
- AstraZeneca
- Sanofi Aventis
- Bristol Myers Squibb
- Novo Nordisk A/S
- Boehringer Ingelheim
- Sanofi Aventis
- Astellas
Key Developments in Russia Diabetes Drugs Industry Industry
- February 2023: AstraZeneca's Forxiga (dapagliflozin) was approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the full spectrum of left ventricular ejection fraction. It includes heart failure with mildly reduced and preserved ejection fraction.
- March 2022: Eli Lilly and Boehringer Ingelheim gained approval for heart failure treatment from the EU for sodium-glucose co-transporter-2-inhibitor, Jardiance (empagliflozin).
Strategic Outlook for Russia Diabetes Drugs Industry Market
The strategic outlook for the Russia diabetes drugs industry is one of continued growth and evolution, driven by unmet medical needs and advancements in therapeutic innovation. The market is expected to witness a sustained demand for both established and novel treatments, with a particular emphasis on affordable and accessible options. Companies will likely focus on expanding their portfolios of oral anti-diabetics, non-insulin injectables, and biosimilar insulins. Strategic partnerships and collaborations will be crucial for navigating the complex regulatory landscape and ensuring effective market penetration. The integration of digital health and personalized medicine approaches will be key differentiators, enhancing patient outcomes and fostering long-term market leadership. The estimated market size for 2025 is over 500 Million, with projections indicating significant upward trends through 2033.
Russia Diabetes Drugs Industry Segmentation
-
1. Insulins
- 1.1. Basal or Long Acting Insulins
- 1.2. Bolus or Fast Acting Insulins
- 1.3. Traditional Human Insulins
- 1.4. Biosimilar Insulins
-
2. Oral Anti-diabetic drugs
- 2.1. Biguanides
- 2.2. Alpha-Glucosidase Inhibitors
- 2.3. Dopamine D2 receptor agonist
- 2.4. SGLT-2 inhibitors
- 2.5. DPP-4 inhibitors
- 2.6. Sulfonylureas
- 2.7. Meglitinides
-
3. Non-Insulin Injectable drugs
- 3.1. GLP-1 receptor agonists
- 3.2. Amylin Analogue
-
4. Combination drugs
- 4.1. Insulin combinations
- 4.2. Oral Combinations
Russia Diabetes Drugs Industry Segmentation By Geography
- 1. Russia
Russia Diabetes Drugs Industry Regional Market Share
Geographic Coverage of Russia Diabetes Drugs Industry
Russia Diabetes Drugs Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 4.50% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. ; The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies
- 3.3. Market Restrains
- 3.3.1 ; Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures
- 3.3.2 Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products
- 3.4. Market Trends
- 3.4.1. The oral anti-diabetic drugs segment holds the highest market share in the Russia Diabetes Drugs Market in the current year
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Russia Diabetes Drugs Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Insulins
- 5.1.1. Basal or Long Acting Insulins
- 5.1.2. Bolus or Fast Acting Insulins
- 5.1.3. Traditional Human Insulins
- 5.1.4. Biosimilar Insulins
- 5.2. Market Analysis, Insights and Forecast - by Oral Anti-diabetic drugs
- 5.2.1. Biguanides
- 5.2.2. Alpha-Glucosidase Inhibitors
- 5.2.3. Dopamine D2 receptor agonist
- 5.2.4. SGLT-2 inhibitors
- 5.2.5. DPP-4 inhibitors
- 5.2.6. Sulfonylureas
- 5.2.7. Meglitinides
- 5.3. Market Analysis, Insights and Forecast - by Non-Insulin Injectable drugs
- 5.3.1. GLP-1 receptor agonists
- 5.3.2. Amylin Analogue
- 5.4. Market Analysis, Insights and Forecast - by Combination drugs
- 5.4.1. Insulin combinations
- 5.4.2. Oral Combinations
- 5.5. Market Analysis, Insights and Forecast - by Region
- 5.5.1. Russia
- 5.1. Market Analysis, Insights and Forecast - by Insulins
- 6. Competitive Analysis
- 6.1. Market Share Analysis 2025
- 6.2. Company Profiles
- 6.2.1 Merck And Co
- 6.2.1.1. Overview
- 6.2.1.2. Products
- 6.2.1.3. SWOT Analysis
- 6.2.1.4. Recent Developments
- 6.2.1.5. Financials (Based on Availability)
- 6.2.2 Pfizer
- 6.2.2.1. Overview
- 6.2.2.2. Products
- 6.2.2.3. SWOT Analysis
- 6.2.2.4. Recent Developments
- 6.2.2.5. Financials (Based on Availability)
- 6.2.3 Takeda
- 6.2.3.1. Overview
- 6.2.3.2. Products
- 6.2.3.3. SWOT Analysis
- 6.2.3.4. Recent Developments
- 6.2.3.5. Financials (Based on Availability)
- 6.2.4 Other
- 6.2.4.1. Overview
- 6.2.4.2. Products
- 6.2.4.3. SWOT Analysis
- 6.2.4.4. Recent Developments
- 6.2.4.5. Financials (Based on Availability)
- 6.2.5 Janssen Pharmaceuticals
- 6.2.5.1. Overview
- 6.2.5.2. Products
- 6.2.5.3. SWOT Analysis
- 6.2.5.4. Recent Developments
- 6.2.5.5. Financials (Based on Availability)
- 6.2.6 Eli Lilly
- 6.2.6.1. Overview
- 6.2.6.2. Products
- 6.2.6.3. SWOT Analysis
- 6.2.6.4. Recent Developments
- 6.2.6.5. Financials (Based on Availability)
- 6.2.7 Novartis
- 6.2.7.1. Overview
- 6.2.7.2. Products
- 6.2.7.3. SWOT Analysis
- 6.2.7.4. Recent Developments
- 6.2.7.5. Financials (Based on Availability)
- 6.2.8 AstraZeneca
- 6.2.8.1. Overview
- 6.2.8.2. Products
- 6.2.8.3. SWOT Analysis
- 6.2.8.4. Recent Developments
- 6.2.8.5. Financials (Based on Availability)
- 6.2.9 Sanofi Aventis
- 6.2.9.1. Overview
- 6.2.9.2. Products
- 6.2.9.3. SWOT Analysis
- 6.2.9.4. Recent Developments
- 6.2.9.5. Financials (Based on Availability)
- 6.2.10 Bristol Myers Squibb
- 6.2.10.1. Overview
- 6.2.10.2. Products
- 6.2.10.3. SWOT Analysis
- 6.2.10.4. Recent Developments
- 6.2.10.5. Financials (Based on Availability)
- 6.2.11 Novo Nordisk A/S
- 6.2.11.1. Overview
- 6.2.11.2. Products
- 6.2.11.3. SWOT Analysis
- 6.2.11.4. Recent Developments
- 6.2.11.5. Financials (Based on Availability)
- 6.2.12 Boehringer Ingelheim
- 6.2.12.1. Overview
- 6.2.12.2. Products
- 6.2.12.3. SWOT Analysis
- 6.2.12.4. Recent Developments
- 6.2.12.5. Financials (Based on Availability)
- 6.2.13 Sanofi Aventis
- 6.2.13.1. Overview
- 6.2.13.2. Products
- 6.2.13.3. SWOT Analysis
- 6.2.13.4. Recent Developments
- 6.2.13.5. Financials (Based on Availability)
- 6.2.14 Astellas
- 6.2.14.1. Overview
- 6.2.14.2. Products
- 6.2.14.3. SWOT Analysis
- 6.2.14.4. Recent Developments
- 6.2.14.5. Financials (Based on Availability)
- 6.2.1 Merck And Co
List of Figures
- Figure 1: Russia Diabetes Drugs Industry Revenue Breakdown (Million, %) by Product 2025 & 2033
- Figure 2: Russia Diabetes Drugs Industry Share (%) by Company 2025
List of Tables
- Table 1: Russia Diabetes Drugs Industry Revenue Million Forecast, by Insulins 2020 & 2033
- Table 2: Russia Diabetes Drugs Industry Volume K Unit Forecast, by Insulins 2020 & 2033
- Table 3: Russia Diabetes Drugs Industry Revenue Million Forecast, by Oral Anti-diabetic drugs 2020 & 2033
- Table 4: Russia Diabetes Drugs Industry Volume K Unit Forecast, by Oral Anti-diabetic drugs 2020 & 2033
- Table 5: Russia Diabetes Drugs Industry Revenue Million Forecast, by Non-Insulin Injectable drugs 2020 & 2033
- Table 6: Russia Diabetes Drugs Industry Volume K Unit Forecast, by Non-Insulin Injectable drugs 2020 & 2033
- Table 7: Russia Diabetes Drugs Industry Revenue Million Forecast, by Combination drugs 2020 & 2033
- Table 8: Russia Diabetes Drugs Industry Volume K Unit Forecast, by Combination drugs 2020 & 2033
- Table 9: Russia Diabetes Drugs Industry Revenue Million Forecast, by Region 2020 & 2033
- Table 10: Russia Diabetes Drugs Industry Volume K Unit Forecast, by Region 2020 & 2033
- Table 11: Russia Diabetes Drugs Industry Revenue Million Forecast, by Insulins 2020 & 2033
- Table 12: Russia Diabetes Drugs Industry Volume K Unit Forecast, by Insulins 2020 & 2033
- Table 13: Russia Diabetes Drugs Industry Revenue Million Forecast, by Oral Anti-diabetic drugs 2020 & 2033
- Table 14: Russia Diabetes Drugs Industry Volume K Unit Forecast, by Oral Anti-diabetic drugs 2020 & 2033
- Table 15: Russia Diabetes Drugs Industry Revenue Million Forecast, by Non-Insulin Injectable drugs 2020 & 2033
- Table 16: Russia Diabetes Drugs Industry Volume K Unit Forecast, by Non-Insulin Injectable drugs 2020 & 2033
- Table 17: Russia Diabetes Drugs Industry Revenue Million Forecast, by Combination drugs 2020 & 2033
- Table 18: Russia Diabetes Drugs Industry Volume K Unit Forecast, by Combination drugs 2020 & 2033
- Table 19: Russia Diabetes Drugs Industry Revenue Million Forecast, by Country 2020 & 2033
- Table 20: Russia Diabetes Drugs Industry Volume K Unit Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Russia Diabetes Drugs Industry?
The projected CAGR is approximately 4.50%.
2. Which companies are prominent players in the Russia Diabetes Drugs Industry?
Key companies in the market include Merck And Co, Pfizer, Takeda, Other, Janssen Pharmaceuticals, Eli Lilly, Novartis, AstraZeneca, Sanofi Aventis, Bristol Myers Squibb, Novo Nordisk A/S, Boehringer Ingelheim, Sanofi Aventis, Astellas.
3. What are the main segments of the Russia Diabetes Drugs Industry?
The market segments include Insulins, Oral Anti-diabetic drugs, Non-Insulin Injectable drugs, Combination drugs.
4. Can you provide details about the market size?
The market size is estimated to be USD 1.04 Million as of 2022.
5. What are some drivers contributing to market growth?
; The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies.
6. What are the notable trends driving market growth?
The oral anti-diabetic drugs segment holds the highest market share in the Russia Diabetes Drugs Market in the current year.
7. Are there any restraints impacting market growth?
; Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures. Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products.
8. Can you provide examples of recent developments in the market?
February 2023: AstraZeneca's Forxiga (dapagliflozin) was approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the full spectrum of left ventricular ejection fraction. It includes heart failure with mildly reduced and preserved ejection fraction.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 3800, USD 4500, and USD 5800 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Russia Diabetes Drugs Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Russia Diabetes Drugs Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Russia Diabetes Drugs Industry?
To stay informed about further developments, trends, and reports in the Russia Diabetes Drugs Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
